Canaccord Genuity Maintains Buy on Definium Therapeutics, Raises Price Target to $64

Benzinga Newsdesk www.benzinga.com Positive 82.8%

Neg 0% Neu 0% Pos 82.8%

Canaccord Genuity analyst Sumant Kulkarni maintains Definium Therapeutics (NASDAQ:DFTX) with a Buy and raises the price target from $58 to $64.